Security
Prelude Therapeutics Incorporated Common Stock · PRLD
PRLDNASDAQCommon stockCurrentCIK 1678660Updated Oct 6, 2026
Name history
Prelude Therapeutics Inc. · through Oct 20, 2017
PRLD price & chart
Loading TradingView…
NASDAQ:PRLD on TradingView ↗About the company
Prelude Therapeutics is a leading precision oncology company developing innovative medicines in areas of high unmet need for cancer patients. Our pipeline features highly selective KAT6A
In the news
Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering ↗
Recent filings
Regulation FD Disclosure
Items 7.01, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
SCHEDULE 13G - filed by Soleus Private Equity Fund III, L.P. regarding Prelude Therapeutics Inc
4 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 94,755,000Source | 197,220,000Source | 189,363,000Source | 114,918,000Source | 224,291,000Source | 119,642,000Source | 141,260,000Source | 247,106,000Source | 141,315,000Source | 175,515,000Source | 277,665,000Source | 220,500,000Source |
| Property, Plant and Equipment, NetUSD | 5,531,000Source | 7,202,000Source | 4,397,000Source | 5,956,000Source | 7,554,000Source | 4,722,000Source | 6,388,000Source | 7,294,000Source | 5,113,000Source | 6,767,000Source | 7,325,000Source | 4,908,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 47,532,000Source | 11,134,000Source | 26,329,000Source | 25,752,000Source | 27,828,000Source | 21,756,000Source | 40,269,000Source | 24,707,000Source | 35,256,000Source | 12,474,000Source | 25,291,000Source | 30,605,000Source |
| Assets, CurrentUSD | 58,330,000Source | 156,387,000Source | 154,898,000Source | 76,876,000Source | 182,714,000Source | 84,593,000Source | 102,403,000Source | 205,366,000Source | 105,692,000Source | 135,895,000Source | 235,589,000Source | 204,380,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 3,373,000Source | 2,761,000Source | 3,141,000Source | 3,660,000Source | 2,870,000Source | 3,039,000Source | 3,329,000Source | 3,442,000Source | 2,478,000Source | 2,281,000Source | 2,654,000Source | 2,652,000Source |
| Operating Lease, Right-of-Use AssetUSD | 27,549,000Source | 29,182,000Source | 26,389,000Source | 27,932,000Source | 29,574,000Source | 26,778,000Source | 28,315,000Source | 30,107,000Source | 27,165,000Source | 28,699,000Source | 30,412,000Source | 1,792,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 36,221,000Source | 40,789,000Source | 55,630,000Source | 39,080,000Source | 42,015,000Source | 59,459,000Source | 38,082,000Source | 36,372,000Source | 72,678,000Source | 44,056,000Source | 40,575,000Source | 25,063,000Source |
| Stockholders’ equity: | ||||||||||||
| Retained Earnings (Accumulated Deficit)USD | -666,604,000Source | -554,832,000Source | -707,367,000Source | -646,879,000Source | -522,561,000Source | -693,446,000Source | -615,648,000Source | -487,821,000Source | -683,061,000Source | -583,563,000Source | -456,390,000Source | -334,558,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 2,000Source | 167,000Source | -227,000Source | -1,000Source | -290,000Source | -41,000Source | 12,000Source | -235,000Source | 8,000Source | 35,000Source | 223,000Source | -1,692,000Source |
| Stockholders' Equity Attributable to ParentUSD | 58,534,000Source | 156,431,000Source | 133,733,000Source | 75,838,000Source | 182,276,000Source | 60,183,000Source | 103,178,000Source | 210,734,000Source | 68,637,000Source | 131,459,000Source | 237,090,000Source | 195,437,000Source |
| Additional Paid in Capital, Common StockUSD | 725,131,000Source | 711,091,000Source | 841,319,000Source | 722,713,000Source | 705,122,000Source | 753,664,000Source | 718,809,000Source | 698,785,000Source | 751,684,000Source | 714,982,000Source | 693,252,000Source | 531,682,000Source |
| Liabilities and EquityUSD | 94,755,000Source | 197,220,000Source | 189,363,000Source | 114,918,000Source | 224,291,000Source | 119,642,000Source | 141,260,000Source | 247,106,000Source | 141,315,000Source | 175,515,000Source | 277,665,000Source | 220,500,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 18,190,000Source | 22,224,000Source | 38,042,000Source | 20,908,000Source | 23,335,000Source | 41,720,000Source | 19,787,000Source | 17,643,000Source | 52,994,000Source | 25,641,000Source | 21,829,000Source | 21,702,000Source |
| Operating Lease, Liability, CurrentUSD | 2,727,000Source | 2,365,000Source | 2,779,000Source | 2,711,000Source | 2,232,000Source | 2,761,000Source | 2,600,000Source | 2,188,000Source | 2,744,000Source | 2,492,000Source | 1,481,000Source | 1,832,000Source |
| Accounts Payable, CurrentUSD | 2,533,000Source | 5,921,000Source | 2,032,000Source | 4,962,000Source | 6,170,000Source | 2,069,000Source | 5,831,000Source | 5,308,000Source | 3,983,000Source | 7,732,000Source | 4,580,000Source | 6,777,000Source |
| Operating Lease, Liability, NoncurrentUSD | 15,127,000Source | 15,412,000Source | 14,871,000Source | 15,206,000Source | 15,465,000Source | 14,960,000Source | 15,267,000Source | 15,452,000Source | 15,045,000Source | 15,325,000Source | 15,407,000Source | — |
| Other Liabilities, NoncurrentUSD | 2,904,000Source | 3,153,000Source | 2,717,000Source | 2,966,000Source | 3,215,000Source | 2,779,000Source | 3,028,000Source | 3,277,000Source | 2,841,000Source | 3,090,000Source | 3,339,000Source | 3,361,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 12,930,000Source | 13,579,000Source | 7,983,000Source | 13,235,000Source | 11,426,000Source | 5,938,000Source | 11,303,000Source | 10,147,000Source | 12,533,000Source | 15,209,000Source | 15,768,000Source | 13,093,000Source |
| Deferred Revenue, CurrentUSD | — | — | 25,248,000Source | — | 3,000,000Source | 30,952,000Source | — | — | 33,734,000Source | — | — | — |
| Deferred Revenue, NoncurrentUSD | — | — | 0Source | — | — | 0Source | — | — | 1,798,000Source | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -10,385,000Source | -32,085,000Source | -99,498,000Source | -127,173,000Source | -121,832,000Source | -115,438,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 391,000Source | 435,000Source | 1,711,000Source | 1,772,000Source | 1,169,000Source | 1,324,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 2,000,000Source | 3,832,000Source | 11,913,000Source | 21,345,000Source | 25,616,000Source | 25,144,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -1,879,000Source | -1,910,000Source | -3,918,000Source | 3,305,000Source | -2,270,000Source | -347,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -21,685,000Source | -34,231,000Source | -56,302,000Source | -102,888,000Source | -107,063,000Source | -83,729,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 8,499,000Source | 62,186,000Source | 53,459,000Source | 90,191,000Source | -34,646,000Source | 81,691,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 0Source | 47,000Source | 67,000Source | 764,000Source | 3,513,000Source | 3,019,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | 51,000Source | 5,000Source | 17,000Source | 54,000Source | 17,000Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -314,000Source | -160,000Source | 24,816,000Source | -120,000Source | 136,395,000Source | 815,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -13,500,000Source | 27,795,000Source | 21,973,000Source | -12,817,000Source | -5,314,000Source | -1,223,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 50,767,000Source | 15,178,000Source | 29,734,000Source | 29,796,000Source | 24,991,000Source | 44,313,000Source | 38,491,000Source | 16,518,000Source | 29,335,000Source | 34,649,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 2,423,000Source | 5,926,000Source | 2,027,000Source | 3,814,000Source | 2,000,000Source | 3,832,000Source | 11,913,000Source | 21,345,000Source | 25,616,000Source | 25,144,000Source |
| General and Administrative ExpenseUSD | — | — | 5,210,000Source | 7,919,000Source | 5,027,000Source | 6,410,000Source | 5,156,000Source | 5,790,000Source | 22,406,000Source | 28,719,000Source | 28,884,000Source | 30,651,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -19,725,000Source | -32,271,000Source | -13,921,000Source | -31,231,000Source | -10,385,000Source | -32,085,000Source | -99,498,000Source | -127,173,000Source | -121,832,000Source | -115,438,000Source |
| Operating ExpensesUSD | — | — | 26,918,000Source | 37,376,000Source | 21,158,000Source | 32,194,000Source | 18,757,000Source | 34,606,000Source | 116,706,000Source | 146,714,000Source | 132,277,000Source | 123,540,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 693,000Source | 2,105,000Source | 1,533,000Source | 963,000Source | 3,792,000Source | 2,521,000Source | 5,068,000Source | 12,541,000Source | 10,445,000Source | 8,102,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 31,000Source | 0Source | 16,000Source | 60,000Source | 47,000Source | 389,000Source |
| Restructuring Costs | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 6,500,000Source | 3,000,000Source | 5,704,000Source | 0Source | 4,580,000Source | 0Source | 12,140,000Source | 7,000,000Source | — | — |
| Operating Income (Loss)USD | — | — | -20,418,000Source | -34,376,000Source | -15,454,000Source | -32,194,000Source | -14,177,000Source | -34,606,000Source | -104,566,000Source | -139,714,000Source | -132,277,000Source | -123,540,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 693,000Source | 2,105,000Source | 1,533,000Source | 963,000Source | 3,792,000Source | 2,521,000Source | 5,068,000Source | 12,541,000Source | 10,445,000Source | 8,102,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -19,725,000Source | -32,271,000Source | -13,921,000Source | -31,231,000Source | -10,385,000Source | -32,085,000Source | -99,498,000Source | -127,173,000Source | -121,832,000Source | -115,438,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.26Source | -0.43Source | -0.14Source | -0.41Source | -0.13Source | -0.42Source | -1.29Source | -1.68Source | -2.02Source | -2.44Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.26Source | -0.43Source | -0.14Source | -0.41Source | -0.13Source | -0.42Source | -1.29Source | -1.68Source | -2.02Source | -2.44Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 76,132,337Source | 75,855,949Source | 98,388,593Source | 75,993,941Source | 82,519,981Source | 75,986,281Source | 76,956,194Source | 75,805,840Source | 60,357,052Source | 47,371,589Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 76,132,337Source | 75,855,949Source | 98,388,593Source | 75,993,941Source | 82,519,981Source | 75,986,281Source | 76,956,194Source | 75,805,840Source | 60,357,052Source | 47,371,589Source |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 5,210,000Source | 7,919,000Source | 5,027,000Source | 6,410,000Source | 5,156,000Source | 5,790,000Source | 22,406,000Source | 28,719,000Source | 28,884,000Source | 30,651,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -99,500,000Source | — | — | — |
| Operating ExpensesUSD | — | — | 26,918,000Source | 37,376,000Source | 21,158,000Source | 32,194,000Source | 18,757,000Source | 34,606,000Source | 116,706,000Source | 146,714,000Source | 132,277,000Source | 123,540,000Source |
| Research and Development ExpenseUSD | — | — | 21,708,000Source | 29,457,000Source | 16,131,000Source | 25,784,000Source | 13,601,000Source | 28,816,000Source | 94,300,000Source | 117,995,000Source | 103,393,000Source | 92,889,000Source |
| Restructuring Costs | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
Filing attachments
prld-ex99_1.htm · 8-K · 2026-09-10
EX-99.1 2 prld-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader Phase 1 study of PRT13722 in patients with HR+ breast cancer anticipated to begin enrolling patients in the fourth quarter of 2026. WILMINGTON, Del., Sep. 10, 2026 (GLOBE NEWSWIRE) - Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that …
Read attachment ↗prld-ex99_2.htm · 8-K · 2026-09-10
EX-99.2 3 prld-ex99_2.htm EX-99.2 Corporate Presentation September 2026 Exhibit 99.2 This presentation contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated discovery, preclinical and clinical development activities for Prelude’s product candidates and milestones, the potential safety, efficacy, benefits and addressable market for Prelude Therapeutics Incorp…
Read attachment ↗prld-ex99_1.htm · 8-K · 2026-08-11
EX-99.1 2 prld-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update The Company expects to initiate its Phase 1 study of PRT13722, a first-in-class highly-selective oral KAT6A degrader in HR+ breast cancer in the fourth quarter Presented preclinical data demonstrating differentiated profile of PRT13722, at the American Association for Cancer Research (AACR) Annual Meeting 2026 Enrollment continues in Pha…
Read attachment ↗prld-ex99_1.htm · 8-K · 2026-05-12
EX-99.1 2 prld-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update Initiated enrollment of Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF) The Company expects to file the IND for PRT13722, first-in-class highly-selective oral KAT6A degrader, by mid-2026 with Phase 1 study initiation in ER+ breast cancer anticipated in the 2H 20…
Read attachment ↗prld-ex99_2.htm · 8-K · 2026-05-12
EX-99.2 3 prld-ex99_2.htm EX-99.2 Corporate Presentation May 2026 Exhibit 99.2 This presentation contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated discovery, preclinical and clinical development activities for Prelude’s product candidates and milestones, the potential safety, efficacy, benefits and addressable market for Prelude Therapeutic Incorporated'…
Read attachment ↗d131537dex41.htm · 8-K · 2026-04-21
EX-4.1 3 d131537dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 PRELUDE THERAPEUTICS INCORPORATED FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. __ Original Issue Date: [ ], 2026 Prelude Therapeutics incorporated, a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered assigns (the “Holder”), is entitled, su…
Read attachment ↗